Choletimb Tablet

Brand Name: Choletimb Tablet 
Active Ingredient: Ezetimibe 10mg

When is Choletimb Tablet prescribed for?

Primary Hypercholesterolemia 
Monotherapy
: Choletimb, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. 

Combination therapy with HMG-CoA reductase inhibitors:
Choletimb, administered in combination with an HMG-CoA reductase inhibitor, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. 

Homozygous Familial Hypercholesterolemia (HoFH)
The combination of Choletimb and Statins, is indicated for, the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable. 

Homozygous Sitosterolemia 
Choletimb is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 

Also Choletimb reduces TG and increases HDL-C in patients with hypercholesterolemia. 

Prior to initiating therapy with Choletimb, secondary causes for dyslipidemia (i.e. diabetes, hypothyroidism, obstructive liver disease, chronic renal failure, and drugs that increase LDL-C and decrease HDL-C [progestins, anabolic steroids, and corticosteroids]), should be excluded or, if appropriate, treated. 

How should you take Choletimb Tablet?
The recommended dose of Choletimb is 10 mg once daily.

Choletimb can be administered with or without food. Choletimb may be administered with an HMG-CoA reductase inhibitor for incremental effect.
For convenience, the daily dose of Choletimb may be taken at the same time as the HMG-CoA reductase inhibitor, according to the dosing recommendations for the HMG- CoA reductase inhibitor.

When Choletimb Tablet must not be prescribed?
Choletimb Tablet must not be used in patients with hypersensitivity to any component of this medication.
The combination of Choletimb with an HMG-CoA reductase inhibitor is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases.

Possible Drug interaction with Choletimb Tablet:

  • Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established.
  • HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin.

Special information if you are pregnant or breastfeeding
there are no adequate and well-controlled studies of Ezetimibe in pregnant women.

Choletimb Tablet should be used during pregnancy only if the potential benefit justifies the risk to the fetus.